key: cord-1000205-zht1yo6l
authors: Comer, S. P.; Cullivan, S.; Szklanna, P. B.; Weiss, L.; Cullen, S.; Kelliher, S.; Smolenski, A.; Moran, N.; Murphy, C.; Altaie, H.; Curran, J.; O'Reilly, K.; Marsh, B.; Gaine, S.; McCullagh, B.; Ni Ainle, F.; Kevane, B.; Maguire, P. B.
title: COVID-19 induces a hyperactive phenotype in circulating platelets
date: 2020-07-26
journal: nan
DOI: 10.1101/2020.07.24.20156240
sha: 94f0e3ee187c6c17a28f01ce39f5dbc9ad2faa73
doc_id: 1000205
cord_uid: zht1yo6l

Background Coronavirus disease 2019 (COVID-19), caused by novel coronavirus SARS-CoV-2, has to date affected over 13.3 million globally. Although high rates of venous thromboembolism and evidence of COVID-19-induced endothelial dysfunction have been reported, the precise aetiology of the increased thrombotic risk associated with COVID-19 infection remains to be fully elucidated. Objectives Here, we assessed clinical platelet parameters and circulating platelet activity in patients with severe and non-severe COVID-19. Methods An assessment of clinical blood parameters in patients with severe COVID-19 disease (requiring intensive care), patients with non-severe disease (not requiring intensive care), general medical in-patients without COVID-19 and healthy donors was undertaken. Platelet function and activity were also assessed by secretion and specific marker analysis. Results We show that routine clinical blood parameters including increased MPV and decreased platelet:neutrophil ratio are associated with disease severity in COVID-19 upon hospitalisation and intensive care unit admission. Strikingly, agonist-induced ADP release was dramatically higher in COVID-19 patients compared with non-COVID-19 hospitalized patients and circulating levels of PF4, sP-selectin and TPO were also significantly elevated in COVID-19. Conclusion Distinct differences exist in routine full blood count and other clinical laboratory parameters between patients with severe and non-severe COVID-19. Moreover, we have determined that COVID-19 patients possess hyperactive circulating platelets. These data suggest that abnormal platelet reactivity may contribute to hypercoagulability in COVID-19. Further investigation of platelet function in COVID-19 may provide additional insights into the aetiology of thrombotic risk in this disease and may contribute to the optimisation of thrombosis prevention and treatment strategies.

Over 13.3 million people globally have been infected since the outbreak of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2; or COVID- 19) in December 2019, with over 578,000 fatalities reported to date (1). COVID-19 is characterised by a marked proinflammatory response with fever, elevated inflammatory markers and clinical & radiological features of pneumonitis being evident among affected individuals (2) . A complex interplay is known to exist between pro-inflammatory pathway activity and blood coagulation activation; this interplay appears to represent a source of morbidity among SARS-CoV-2 infected patients, particularly among those with severe disease (3) . Unexpectedly high levels of venous thromboembolism (VTE) (4) (5) (6) (7) (8) (9) (10) have been reported in this patient group and levels of D-dimer (a marker of increased blood coagulation activation) have been shown to correlate with disease severity and appear to be predictive of mortality (11, 12) . COVID-19 patients with cardiovascular risk factors (hypertension, diabetes) have been indentified as being particularly at risk of thrombotic events (13) (14) (15) (16) . Moreover, recent post-mortem studies have shown evidence of widespread thrombosis in pulmonary vasculature and other organs (17, 18) .

Anti-platelet drugs (such as aspirin) and anti-coagulants (such as low molecular weight heparin (LMWH)) are known to be effective in the prevention and treatment of arterial and venous thrombosis (19) (20) (21) . High rates of VTE despite LMWH thromboprophylaxis have been reported in COVID-19 and emerging reports of unusual or severe arterial thrombotic events have been published (5, 18, (22) (23) (24) . As both arterial and venous thrombosis can have devastating consequences, efforts to determine the precise molecular mechanisms underlying the unique hypercoagulable state in COVID-19 must be prioritised in order to optimise preventative and therapeutic strategies (25, 26) .

Circulating platelets, the activity of which are central to haemostasis and thrombosis, are now understood to fulfill a much broader role in the regulation of a myriad of biological processes including inflammation, wound healing and angiogenesis (27) . Platelet-mediated immune responses induced by viral infection have previously been reported (28) (29) (30) (31) and a recent report has demonstrated altered platelet gene expression profiles and functional responses in patients infected with COVID-19 (32) . Moreover, thrombocytopenia has been noted in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.24.20156240 doi: medRxiv preprint response to dengue (33, 34) and SARS-CoV infection (35) and among in-patients with COVID-19, thrombocytopenia appears to be associated with increased risk of in-hospital mortality (3, 36) . Increased mean platelet volume (MPV), a sensitive indicator of circulating platelet activity and a prognostic marker in thromboinflammation (37) (38) (39) , has also been reported in association with specific viral infections (40) .

In the present study, we aimed to characterise patterns of platelet activity among patients infected with COVID-19 relative to that observed in non-affected hospitalised patients in order to determine if platelet dysfunction or hyperactivity contributes to COVID-19-induced hypercoagulability.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 26, 2020. followed by centrifugation (600 xg for 10 min at RT). Platelets were again resuspended in modified Tyrode's buffer and incubated at 37 o C until the ATP secretion assay was performed. Platelet counts were obtained so that the secretion assay results could be normalised to 10 6 platelets/ml. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.24.20156240 doi: medRxiv preprint ATP secretion was measured using a luminescence-based assay, as previously described (41) (42) (43) (44) . Agonists and buffer (5μl), were dispensed in duplicate into 96-well plates, together with 35μl of washed platelets and incubated for 3 minutes at 37 °C, with fast orbital shaking. The doses of platelet agonists used to induce platelet ATP secretion were as follows; thrombin: 0.1 U/ml, 0.5 U/ml; U46619: 1 μ M, 6.6 μ M. Following incubation, 5μl of ATP detecting reagent (chronolume; Labmedics, UK) was dispensed into each well and luminescence was measured immediately using a Perkin Elmer 1420 96-well plate reader. Data was expressed as the amount of ATP secreted, in luminescence arbitrary units (AU), and converted to pmoles ATP released per 10 6 platelets by comparison with the luminescence recorded from an ATP standard (0.4 mM).

ELISAs for thrombopoietin (DTP00b), P-selectin (DPSE00), and platelet factor 4 (DPF40)

were purchased from R&D Systems (Abingdon, UK) and performed according to the manufactures instructions. In brief, undiluted or 1:40 diluted platelet poor plasma (PPP) was added in triplicate to wells for thrombopoietin and PF4, respectively. After incubation, the plates were washed and incubated with the respective conjugate. For P-selectin, 1:20 diluted PPP was added simultaneously with the P-selectin conjugate and incubated. Again, plates were washed and the substrate added. The reaction was stopped with stop solution and the optical density was determined at 450 nm within 30 minutes on a Dynex DS2 (Dynex Technologies, Worthing, UK). Protein quantification was performed using a 4 parametric logistic or log-logit regression.

Statistical analysis was performed using R (version 4.0.0) and SAS Viya© software (version 3.5). Data were tested for normal distribution using a Shapiro-Wilk test. Normally distributed continuous FBC data were presented as mean ± standard deviation and assessed for statistical significance using a one-way ANOVA. Differences in ATP release and protein expression were determined using a two-tailed t-test. In both cases, p-values were adjusted for multiple comparisons using a Holm-Bonferroni post-hoc test. Categorical data were described as percentages and significance was tested using a Fisher's exact test. Values below 0.05 were regarded as statistically significant. Data visualisation was performed using SAS Viya©.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.24.20156240 doi: medRxiv preprint

Clinical laboratory data were available for 54 patients with confirmed SARS-CoV-2 infection. Within this group, 34 patients had developed severe disease requiring transfer to the intensive care unit (ICU) for ventilatory support while the remaining 20 patients did not require critical care support at any stage during the course of their hospital admission.

Laboratory parameters relating to these two distinct subgroups of patients with COVID-19

(severe COVID-19, n=34; non-severe COVID-19, n=20) were compared to data from an age and gender-matched cohort of hospitalised medical inpatients without COVID-19 (n=20).

Day of admission was defined as the day patients were admitted to the Mater Misericordiae University Hospital.

In agreement with previous studies (45, 46) , higher levels of D-dimer were observed on the day of hospital admission among the patients who subsequently developed severe COVID-19 (mean±SD; 4.95±6.36 mg/L) in comparison (p=0.0.012) to that observed in the non-severe COVID-19 group (1.01±0.75 mg/L) (Table 1) . Furthermore, a significantly higher mean platelet volume (MPV, p=0.015) and neutrophil count (p=0.013) in addition to a significantly lower platelet-neutrophil ratio (PNR, p=0.0067) was noted on the day of admission in the group of patients who subsequently developed a severe disease course relative to that seen in the non-severe group (Fig. 1A ). Interestingly these significant differences remained following transfer to intensive care (Fig. 1B) .

While platelet counts did not differ on the day of admission between patients subsequently designated to have had either a severe or non-severe disease course (Fig. 1A) , significantly decreased platelet counts were observed among the severe COVID-19 patients at the time of transfer to the ICU relative to the non-severe group (p=0.014, Fig. 1B ). These findings are in agreement with previous studies, which have suggested that a lower platelet count is associated with severe COVID-19 (3, (47) (48) (49) ). An increased neutrophil-to-lymphocyte ratio (NLR) in severe cases relative to non-severe was also detected at the time of hospital admission (another previously reported predictor of disease severity) (Supplementary Fig. 1 ) (47, 50, 51) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.24.20156240 doi: medRxiv preprint

Recently published data have suggested a crucial mechanistic role for platelets in the pathophysiology of COVID-19 (18, 32, 52) . We assessed dense granule release following platelet activation with various platelet agonists. ATP secretion was used as a surrogate marker for dense granule secretion, given that the ratio of ADP to ATP in platelet dense granules is a constant 2:3 ratio (53). Table 2 ). These data suggest that platelets from COVID-19 patients are more responsive to low dose agonist stimulation when compared to control platelets, potentially indicating a reduced activation threshold in COVID-19 patients.

To further characterise this hyperactive platelet phenotype, circulating plasma markers of platelet activity were measured in each of the above study groups (n=6 per group; plateletpoor plasma was available from an additional 2 non-severe COVID patients and an additional . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.24.20156240 doi: medRxiv preprint 3 hospitalised controls). Circulating levels of platelet factor 4 (PF4) were substantially elevated in COVID-19 patients when compared to both hospitalised (HoC) and healthy controls (HeC) (p=0.012 and p=0.0033, respectively; Fig. 3A ). Nonetheless circulating PF4 levels could not differentiate between severe and non-severe COVID-19 patient cohorts (p=0.85). On the other hand, circulating levels of soluble P-selectin (sCD62P) also increased in COVID-19 patients when compared to our control cohorts (Fig. 3B) and intriguingly, could differentiate between our non-severe and severe COVID-19 cohorts (p=0.037), suggesting that elevated sP-selectin may be associated with disease severity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.24.20156240 doi: medRxiv preprint

We have demonstrated that distinct platelet-related patterns in full blood count and other clinical laboratory parameters appear to be associated with the development of a more severe disease course in our cohort of COVID-19 patients, reflecting other recently published data (2, 47, 55) . Therewithal, we also report novel findings which indicate that COVID-19 is associated with abnormal platelet reactivity. Our observations are likely to be of significant clinical and translational relevance in view of the uncertainty that currently exists with regards to the aetiology of thrombotic risk in COVID-19 and the optimal strategy for prevention and treatment of thrombosis in this population.

In addition to the previously reported observations that neutrophilia, lymphopenia, elevated D-dimer, elevated neutrophil-to-lymphocyte ratio and elevated platelet-to-lymphocyte ratio appear to be associated with severe disease, we have reported that within our cohort a significantly lower platelet-to-neutrophil ratio was observed on the day of admission among the COVID-19 patients who subsequently progressed to require critical care support (5, 11, 12, 47, 56) . While platelet counts did not specifically differ between groups on day of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.24.20156240 doi: medRxiv preprint

The circulating levels of the platelet activation markers PF4 and sP-selectin were highly elevated among our cohort of COVID-19 positive patients compared to controls which futher supports the hypothesis that COVID-19 is associated with enhanced platelet activation. The elevated levels of TPO in COVID-19 also aligned with previous findings (32) . While circulating levels of PF4 did not differentiate between severe and non-severe COVID-19 cases, sP-selectin was higher among the severe COVID-19 group, in keeping with previous reports (60, 62) . Other investigators have also reported that sP-selectin levels were elevated in COVID-19 complicated by acute respiratory distress syndrome (ARDS) (63), with even higher levels detected in patients who subsequently died (64) . The mechanism underlying platelet activation in COVID-19 has been speculated to involve MAP kinase pathway (32) and/or PKCδ (60) activation, however the initial trigger remains unidentified. Crucially, Zaid This study has a number of limitations. Firstly, our cohort of patients is relatively small, a factor which (at least in part) is likely to be related to the success of the Irish healthcare system in suppressing transmission of the virus during the early stages of the pandemic.

Additionally, given the public health restrictions that were in place during the period of this study, recruitment of healthy controls was substantially impeded and consequently the available healthy controls were not appropriately matched for age relative to our COVID-19 group and hospitalised control group. Due to the small sample size, adjustment for confounding factors was not possible.

In conclusion, it has been apparent since the early stages of the COVID-19 pandemic that derangements of haemostasis represent a hallmark of this disease and appear to be associated with significant morbidity (12, 69) . Several investigators have reported data suggesting that rates of venous thromboembolism are high in this population and that these thrombotic complications appear to occur despite compliance with standard VTE prevention protocols (5, 7) . Reports of unusual and devastating cases of arterial thrombosis are also emerging (18, (22) (23) (24) . The safety and efficacy of conventional anti-platelet and anti-coagulant treatment strategies in the management of this thrombotic risk is becoming a major focus of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.24.20156240 doi: medRxiv preprint translational and clinical interest. The aetiology of hypercoagulability in COVID-19 is likely multi-factorial but it is presumed to be driven by the marked inflammatory response which arises following infection (70, 71) . It remains to be determined whether standard thrombosis prevention strategies require modification in order to be effective in the prevention of 'immunothrombosis' in COVID-19 or if prevention strategies should focus instead on addressing the 'upstream' inflammatory response driving coagulation activation. Our data indicate that platelets from patients infected with COVID-19 display a hyperactive phenotype, a factor which may contribute to thrombotic risk. Consequently, further characterisation of platelet dysfunction in COVID-19 and the evaluation of anti-platelet therapy as an adjunct to current thrombosis prevention measures is clearly warranted.

Ireland for their dedication and professionalism during the COVID-19 pandemic.

The authors declare that they have no actual or potential conflicts of interest with the contents of this article. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. Platelet dense granule release was measured in duplicate in severe (n=5) and non-severe (n=4) COVID-19 patients compared to hospitalised (n=3) and healthy controls (n=6).

Platelets were stimulated with 0.1 U/ml thrombin (A), 0.5 U/ml thrombin (B), 1 µM U46619 (C), and 6.6 µM U46619 (D) and ATP release (surrogate for ADP) was measured using a Chronolume luciferase assay. ADP release is expressed as pmol/10 6 platelets. Statistical analysis was performed using a two-tailed t-test and p-values were adjusted for multiple comparisons using a Holm-Bonferroni post hoc test. COVID-19 compared to hospitalized (n=6) and healthy (n=6) controls were measured in triplicate by ELISA. Statistical analysis was performed using a two-tailed t-test and p-values were adjusted for multiple comparisons using a Holm-Bonferroni post hoc test.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.24.20156240 doi: medRxiv preprint

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of Coronavirus Disease 2019 in China

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty

The need to manage the risk of thromboembolism in COVID-19 patients

Hypertension and COVID-19

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series

Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Annals of internal medicine

Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis

Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty

Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description

Severe arterial thrombosis associated with Covid-19 infection

Risk of peripheral arterial thrombosis in COVID-19

COVID-19 and its implications for thrombosis and anticoagulation

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

The Era of Thromboinflammation: Platelets Are Dynamic Sensors and Effector Cells During Infectious Diseases

Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past

Platelets in Immune Response to Virus and Immunopathology of Viral Infections

Platelets: essential components of the immune system

Platelet Gene Expression and Function in COVID-19 Patients

Platelet activation determines the severity of thrombocytopenia in dengue infection

Dengue virus nonstructural protein 1 activates platelets via Toll-like receptor 4, leading to thrombocytopenia and hemorrhage

Role of vascular cell adhesion molecules and leukocyte apoptosis in the lymphopenia and thrombocytopenia of patients with severe acute respiratory syndrome (SARS)

Thrombocytopenia and its association with mortality in patients with COVID-19

Platelet size: measurement, physiology and vascular disease

Mean platelet volume: a link between thrombosis and inflammation? Current pharmaceutical design

Large and small platelets-(When) do they differ?

Association of Mean Platelet Volume with Severity, Serology & Treatment Outcome in Dengue Fever: Prognostic Utility

Platelets -Allies of Tumour Cells. In: The Non-Thrombotic Role of Platelets in Health and Disease: InTech

Platelet signalling networks: pathway perturbation demonstrates differential sensitivity of ADP secretion and fibrinogen binding

1174, 6, 8 passim. 44. Mitrugno A, Williams D, Kerrigan SW, Moran N. A novel and essential role for FcgammaRIIa in cancer cell-induced platelet activation

D-dimer in patients infected with COVID-19 and suspected pulmonary embolism

D-dimer levels on admission to predict inhospital mortality in patients with Covid-19

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis

The role of Mean Platelet Volume/platelet count Ratio and Neutrophil to Lymphocyte Ratio on the risk of Febrile Seizure

Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019

Guidelines on platelet function testing. The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force

Thrombopoietin levels increased in patients with severe acute respiratory syndrome

Clinical and immunological features of severe and moderate coronavirus disease 2019

Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19

Studies of biological functions in blood cells from individuals with large platelets

The role of mean platelet volume in predicting thrombotic events

Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis

Platelets can contain SARS-CoV-2 RNA and are hyperactivated in COVID-19

Inflammatory signaling in dengue-infected platelets requires translation and secretion of nonstructural protein 1

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology

Covid-19, Angiogenesis, and ARDS Endotypes

Soluble form of P-selectin in plasma is elevated in acute lung injury. American journal of respiratory and critical care medicine

The role of platelets in mediating a response to human influenza infection

Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation

Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspases

HIV-1 Tat-induced platelet activation and release of CD154 contribute to HIV-1-associated autoimmune thrombocytopenia

COVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection

Coagulopathy in COVID-19

The unique characteristics of COVID-19 coagulopathy

We thank John Crumlish, Áine Lennon, Jane Culligan, Charlotte Prior, Wendy Keogh and Julie McAndrew of the Department of Pathology, Mater Misericordiae University Hospital, for the help in preparing blood samples and ELISA experiments. We also thank Annette Wallace of Conway Stores for her invaluable help. We also thank all patients who gave consent and donated blood to this study. Finally, we thank all frontline healthcare workers in